Faculty of Residency, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia.
Department of Pathology, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia.
Cells. 2021 Mar 11;10(3):621. doi: 10.3390/cells10030621.
Cancer stem cells (CSCs), known also as tumor-initiating cells, are quiescent, pluripotent, self-renewing neoplastic cells that were first identified in hematologic tumors and soon after in solid malignancies. CSCs have attracted remarkable research interest due to their role in tumor resistance to chemotherapy and radiation treatment as well as recurrence. Extensive research has been devoted to the role of CSCs in glioblastoma multiforme (GBM), the most common primary brain tumor in adults, which is characterized by a dismal prognosis because of its aggressive course and poor response to treatment. The aim of the current paper is to provide an overview of current knowledge on the role of cancer stem cells in the pathogenesis and treatment resistance of glioblastoma. The six regulatory mechanisms of glioma stem cells (GSCs)-tumor microenvironment, niche concept, metabolism, immunity, genetics, and epigenetics-are reviewed. The molecular markers used to identify GSCs are described. The role of GSCs in the treatment resistance of glioblastoma is reviewed, along with future treatment options targeting GSCs. Stem cells of glioblastoma thus represent both a driving mechanism of major treatment difficulties and a possible target for more effective future approaches.
癌症干细胞(CSC),也称为肿瘤起始细胞,是静止的、多能的、自我更新的肿瘤细胞,最初在血液肿瘤中被发现,随后在实体恶性肿瘤中被发现。CSC 因其在化疗和放疗抵抗以及复发中的作用而引起了极大的研究兴趣。大量研究致力于 CSC 在多形性胶质母细胞瘤(GBM)中的作用,GBM 是成人中最常见的原发性脑肿瘤,由于其侵袭性病程和对治疗的反应不佳,预后不良。本文的目的是概述 CSC 在胶质母细胞瘤发病机制和治疗耐药性中的作用。综述了胶质瘤干细胞(GSC)的六个调节机制——肿瘤微环境、生态位概念、代谢、免疫、遗传和表观遗传学。描述了用于鉴定 GSC 的分子标记物。综述了 GSC 在胶质母细胞瘤治疗耐药性中的作用,以及针对 GSC 的未来治疗选择。因此,胶质母细胞瘤的干细胞既是主要治疗困难的驱动机制,也是未来更有效方法的可能靶点。